Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting
76 studies found for:    "Multiple Sclerosis, Chronic Progressive"
Show Display Options
Rank Status Study
1 Completed Lipoic Acid for Secondary Progressive Multiple Sclerosis (MS)
Condition: Multiple Sclerosis, Chronic Progressive
Interventions: Drug: lipoic acid;   Drug: Placebo
2 Completed Efficacy of Cyclophosphamide Versus Methylprednisolone in Patients With Secondary Progressive Multiple Sclerosis
Condition: Multiple Sclerosis, Chronic Progressive
Interventions: Drug: Cyclophosphamide (drug);   Drug: Methylprednisolone (drug)
3 Unknown  Safety Study of RTL1000 (Recombinant T Cell Receptor Ligand) in Subjects With Multiple Sclerosis
Conditions: Multiple Sclerosis, Chronic Progressive;   Multiple Sclerosis, Relapsing-Remitting
Interventions: Drug: RTL1000 (recombinant T cell receptor ligand);   Drug: RTL1000 Placebo
4 Not yet recruiting Tolerogenic Dendritic Cells as a Therapeutic Strategy for the Treatment of Multiple Sclerosis Patients (TOLERVIT-MS)
Conditions: Multiple Sclerosis, Relapsing-Remitting;   Multiple Sclerosis, Chronic Progressive
Interventions: Drug: Autologous VitD3 tolerogenic monocyte-derived dendritic cells loaded with a pool of myelin peptides (tolDC-VitD3);   Drug: Interferon-beta
5 Completed Use on Human Beings of Mix of Known Drugs for New Destination - MS Treatment
Conditions: Multiple Sclerosis;   Autoimmune Disease;   Disseminated or Multiple Sclerosis Nos;   Multiple Sclerosis, Acute Relapsing;   Multiple Sclerosis, Primary Progressive;   Multiple Sclerosis, Chronic Progressive
Interventions: Drug: Tetracycline;   Drug: statin;   Drug: antimycotic;   Drug: Fingolimod;   Drug: copaxone
6 Temporarily not available Use of Well Known Drugs for New Destination - MS Improvement (MSNT)
Conditions: Multiple Sclerosis;   Autoimmune Diseases;   Disseminated or Multiple Sclerosis Nos;   Multiple Sclerosis, Acute Relapsing;   Multiple Sclerosis, Primary Progressive;   Multiple Sclerosis, Chronic Progressive
Intervention: Drug: Tetracycline - Statin - Antimycotic
7 Recruiting Intrathecal Rituximab in Progressive Multiple Sclerosis
Conditions: Multiple Sclerosis, Chronic Progressive;   Nervous System Diseases
Interventions: Drug: Rituximab IT;   Drug: methylprednisolone IV;   Drug: Rituximab IV
8 Recruiting Rotating Frame Relaxation Imaging in Patients With Multiple Sclerosis
Conditions: Multiple Sclerosis;   Multiple Sclerosis, Relapsing-Remitting;   Multiple Sclerosis, Chronic Progressive
Intervention: Other: Brain MRI
9 Completed China Betaferon Adherence, Coping and Nurse Support Study
Condition: Multiple Sclerosis, Chronic Progressive
Intervention: Drug: Interferon beta-1b (Betaseron, BAY86-5046)
10 Unknown  Evaluation of Efficiency of Ritalin in Multiple Sclerosis (MS) Patients
Conditions: Relapsing Remitting Multiple Sclerosis;   Multiple Sclerosis, Chronic Progressive
Intervention: Drug: Ritalin
11 Completed Safety Study of an Immunomodulating Microparticle to Treat Progressive Multiple Sclerosis
Conditions: Secondary Progressive Multiple Sclerosis;   Primary Progressive Multiple Sclerosis
Intervention: Biological: MIS416
12 Completed Sunphenon in Progressive Forms of Multiple Sclerosis
Condition: Multiple Sclerosis
Interventions: Drug: Sunphenon EGCG;   Drug: Placebo
13 Not yet recruiting Hydroxychloroquine in Primary Progressive Multiple Sclerosis
Condition: Multiple Sclerosis, Primary Progressive
Intervention: Drug: Hydroxychloroquine
14 Available Expanded Access Program for Ocrelizumab in Participants With Primary Progressive Multiple Sclerosis
Condition: Multiple Sclerosis
Intervention: Drug: Ocrelizumab
15 Active, not recruiting Pharmacokinetics of DMF and the Effects of DMF on Exploratory Biomarkers
Condition: Multiple Sclerosis
Intervention: Drug: BG00012 (DMF) (Tecfidera®.)
16 Recruiting Mitochondrial Dysfunction and Disease Progression
Conditions: Clinically Isolated Syndrome;   Relapsing-Remitting Multiple Sclerosis;   Secondary Progressive Multiple Sclerosis;   Primary Progressive Multiple Sclerosis
Intervention:
17 Recruiting A Phase 1b, Open-label Study of Liothyronine in MS
Conditions: Multiple Sclerosis, Relapsing-Remitting;   Multiple Sclerosis, Secondary Progressive;   Multiple Sclerosis, Primary Progressive
Intervention: Drug: liothyronine
18 Active, not recruiting Autologous Mesenchymal Stromal Cells for Multiple Sclerosis
Conditions: Relapsing-Remitting Multiple Sclerosis;   Secondary Progressive Multiple Sclerosis
Interventions: Drug: XCEL-MC-ALPHA;   Drug: Placebo
19 Terminated BG00012 and Disability Progression in Secondary Progressive Multiple Sclerosis (SPMS)
Condition: Multiple Sclerosis, Secondary Progressive
Interventions: Drug: dimethyl fumarate;   Other: Placebo
20 Active, not recruiting Mechanistic Studies of Phase III Trial With BAF312 in Secondary Progressive Multiple Sclerosis
Condition: Secondary Progressive Multiple Sclerosis
Interventions: Procedure: Blood Draw;   Procedure: CSF collection by lumbar puncture (Optional)

   Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results    Last Page
Indicates status has not been verified in more than two years